UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 1, 2017
VITRO DIAGNOSTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Nevada | 0-17378 | 84-1012042 |
(State or other jurisdiction | Commission File | (I.R.S. Employer Identification number) |
4621 Technology Drive, Golden CO 80403
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (303) 999-2130
______________________________________________________
(Former name or former address, if changed since last report)
___ | Written communications pursuant to Rule 425 under the Securities Act |
___ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act |
___ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act |
___ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
ITEM 1.02
TERMINATION OF A MATERIAL DEFINITIVE AGREEMENTS
Effective June 1, 2017 the previously announced Memorandum of Understanding (“MOU”) between Vitro Diagnostics, Inc. (the “Company”) and Caribbean GC Development Fund, Ltd., a Grand Cayman corporation (“Caribbean GC”) has been terminated without consummation.
The Company has no plans to further pursue the matter.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
| Vitro Diagnostics, Inc. | |
|
|
| |
| Dated: June 1, 2017 | /s/ James R. Musick | |
|
| James R. Musick, President and Chief Executive Officer | |
2